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Neurobiology of Disease
A40 Reduces P-Glycoprotein at the Blood–Brain Barrier
through the Ubiquitin–Proteasome Pathway
Anika M.S. Hartz,1,2,3 X Yu Zhong,1 Andrea Wolf,3 Harry LeVine, III,1 David S. Miller,4 and Björn Bauer3,5
1Sanders-Brown Center on Aging and 2Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, Kentucky 40536,
3Department of Pharmacy Practice and Pharmaceutical Sciences, College of Pharmacy, University of Minnesota, Duluth, Minnesota 55812, 4Laboratory of
Signal Transduction, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina 27709, and
5Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40536
Failure to clear amyloid- (A) from the brain is in part responsible for A brain accumulation in Alzheimer’s disease (AD). A critical
protein for clearing A across the blood– brain barrier is the efflux transporter P-glycoprotein (P-gp) in the luminal plasma membrane
of the brain capillary endothelium. P-gp is reduced at the blood– brain barrier in AD, which has been shown to be associated with A brain
accumulation. However, the mechanism responsible for P-gp reduction in AD is not well understood. Here we focused on identifying
critical mechanistic steps involved in reducing P-gp in AD. We exposed isolated rat brain capillaries to 100 nM A40, A40, aggregated
A40, and A42. We observed that only A40 triggered reduction of P-gp protein expression and transport activity levels; this occurred
in a dose- and time-dependent manner. To identify the steps involved in A-mediated P-gp reduction, we inhibited protein ubiquitina-
tion, protein trafficking, and the ubiquitin–proteasome system, and monitored P-gp protein expression, transport activity, and P-gp-
ubiquitin levels. Thus, exposing brain capillaries to A40 triggers ubiquitination, internalization, and proteasomal degradation of P-gp.
These findings may provide potential therapeutic targets within the blood– brain barrier to limit P-gp degradation in AD and improve A
brain clearance.
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Introduction
The etiology of excess amyloid- (A) brain accumulation in
Alzheimer’s disease (AD) is poorly understood. One contributing
factor to A brain accumulation is reduced A clearance from
the brain (Zlokovic and Frangione, 2003; Zlokovic, 2005). A
neurovascular component in A clearance has been impli-
cated, suggesting that the blood– brain barrier is key in this
process (Zlokovic and Frangione, 2003; Zlokovic, 2005). Stud-
ies show that P-glycoprotein (P-gp), an efflux transporter in
the luminal plasma membrane of brain capillaries, is critical
for clearing A from brain into blood (Lam et al., 2001; Cirrito
et al., 2005; Kuhnke et al., 2007; Hartz et al., 2010). We and
others showed that P-gp protein expression and transport ac-
tivity levels are reduced in brain capillaries from AD mouse
models, suggesting a link between high A levels and reduced
levels of brain capillary P-gp (Hartz et al., 2010; Mehta et al.,
2013).
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Significance Statement
The mechanism reducing blood– brain barrier P-glycoprotein (P-gp) in Alzheimer’s disease is poorly understood. In the present
study, we focused on defining this mechanism. We demonstrate that A40 drives P-gp ubiquitination, internalization, and
proteasome-dependent degradation, reducing P-gp protein expression and transport activity in isolated brain capillaries. These
findings may provide potential therapeutic avenues within the blood– brain barrier to limit P-gp degradation in Alzheimer’s
disease and improve A brain clearance.
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Indeed, an inverse relationship between A and P-gp protein
levels has been observed in postmortem human brain samples
(Wijesuriya et al., 2010; Jeynes and Provias, 2011), and capillary
P-gp levels are significantly reduced and even undetectable in
brain regions with high A levels (Vogelgesang et al., 2002, 2004).
Carrano et al. (2014) demonstrated that P-gp protein levels are
reduced in human brain microvessels affected by high microvas-
cular A load in cerebral amyloid angiopathy. This was not ob-
served in healthy individuals and AD patients without vascular
amyloid deposits. Finally, PET studies in patients with mild and
advanced AD confirmed that P-gp-mediated transport of [ 11C]-
verapamil at the blood– brain barrier is lower than that in age-
matched healthy individuals (van Assema et al., 2012; Deo et al.,
2014). Collectively, these findings demonstrate an association be-
tween A brain levels and blood– brain barrier P-gp. They sug-
gest that P-gp is critical for A clearance and that reduced P-gp
protein expression and transport activity result in excessive A
brain accumulation.
The mechanism reducing blood– brain barrier P-gp in AD is
poorly understood. In the present study, we focused on defining
this mechanism. We demonstrate that A40 drives P-gp
ubiquitination-, internalization-, and proteasome-dependent
degradation, reducing P-gp protein expression and transport ac-
tivity in isolated brain capillaries. These findings may provide
potential therapeutic avenues within the blood– brain barrier to
limit P-gp degradation in AD and improve A brain clearance.
Materials and Methods
Chemicals. A11 antibody against A40 oligomers, C219 antibody against
P-gp, and antibodies against RAGE and -actin were purchased from
Abcam. Antibodies against LRP and ubiquitin, and purified IgG control
antibody were obtained from Calbiochem-Novabiochem. OC antibody
against A40 was purchased from EMD Millipore, and antibodies 6E10
and 4G8, which recognize both A40 and A42, were obtained from
Covance. Pierce Protein A/G Plus beaded agarose resin was obtained
from Thermo Scientific, and the 20 S Proteasome Assay kit was pur-
chased from Cayman Chemical. PYR-41 and bortezomib were from
Selleckchem. [N- (4-Nitrobenzofurazan-7-yl)-D-Lys8]-cyclosporin A
(NBD-CSA) was custom-synthesized by R. Wenger (Basel, Switzerland)
(Schramm et al., 1995). PSC833 was a kind gift from Novartis. AggreSure
-Amyloid (1– 40) (#AS-72215) was obtained from AnaSpec. Human
A1– 40 (A40), A1– 42 (A42), and A40 –1reverse (A40reverse) and
all other chemicals were purchased from Sigma-Aldrich.
Animals. All animal experiments were approved by the Institutional
Animal Care and Use Committee of the University of Kentucky and
University of Minnesota (UK protocol #2014 –1233, principal investiga-
tor A.M.S.H.; UMN protocol #0710A17842 and #1110A05865, principal
investigator A.M.S.H.) and performed in strict accordance with Associ-
ation for Assessment and Accreditation of Laboratory Animal Care reg-
ulations, the Department of Agriculture Animal Welfare Act, and the
Guide for the Care and Use of Laboratory Animals of the National Insti-
tutes of Health. Male Sprague Dawley rats (CD IGS rats; 275–300 g; 8 –10
weeks) were purchased from Charles River. After shipping, rats were
allowed to adapt to the new environment for a minimum of 5 d before
they were used for experiments. Rats were kept under controlled envi-
ronmental conditions (23°C, 35% relative humidity, 12 h dark-light cy-
cle) with free access to tap water and standard rodent chow.
A ELISA. Total and oligomer-specific A measurements were per-
formed by ELISA (LeVine, 2004). Capture antibodies were immobilized
on ELISA plates (Costar 9018). Total (monomeric  oligomeric) A40
was determined by capturing with monoclonal antibody 6E10 (amino
acids 3– 8) and detecting with biotinylated monoclonal antibody 4G8
(amino acids 17–24). Oligomeric hA40 was determined by capturing
with nonbiotinylated 4G8 and detecting with biotinylated 4G8 antibody.
Capturing and detecting with the 4G8 antibodies to the same epitope
recognize only oligomeric A40 because the 4G8 epitope in the A
monomer is sequestered by the capture antibody and is not accessible to
the biotinylated 4G8. The bound biotinylated 4G8 is quantified by
streptavidin-HRP (Rockland Immunochemicals) and H2O2/tetrameth-
ylbenzidine peroxidase substrate.
Brain capillary isolation. Rat brain capillaries were isolated as previ-
ously described (Hartz et al., 2004, 2008, 2010; Bauer et al., 2006). Briefly,
rats were killed by CO2 inhalation and decapitated. Brains were removed,
cleaned, dissected, and homogenized in ice-cold PBS (2.7 mM KCl, 1.46
mM KH2PO4, 136.9 mM NaCl, 8.1 mM Na2HPO4, supplemented with 5
mM D-glucose and 1 mM sodium pyruvate, pH 7.4). Ficoll PM400 was
added to the homogenate to a final concentration of 15%, and the Ficoll-
brain homogenate mix was centrifuged at 5800  g for 20 min at 4°C.
After resuspending the pellet in PBS containing 1% BSA (w/v), the cap-
illary suspension was passed over a 40 ml glass bead column (0.4 – 0.6
mm; Sartorius StedimBiotech). Capillaries adhering to the glass beads
were washed off the beads and collected in 1% BSA. Capillaries were
washed with PBS (BSA-free) and used for experiments.
P-gp transport assay. To determine P-gp transport activity, freshly iso-
lated brain capillaries were incubated for 1 h at room temperature with
the fluorescent P-gp-specific substrate NBD-CSA (2 M in PBS buffer)
(Hartz et al., 2004, 2008, 2010). For each treatment, images of 10 capil-
laries were acquired by confocal microscopy using a Zeiss LSM 710 in-
verted confocal microscope with a 40 1.2 NA water-immersion
objective and using the 488 nm line of an argon laser (Carl Zeiss). Images
were analyzed by quantitating NBD-CSA fluorescence in the capillary
lumen using ImageJ version 1.45s (Wayne Rasband, National Institutes
of Health). Specific, luminal NBD-CSA fluorescence was taken as the
difference between total luminal fluorescence and fluorescence in the
presence of the P-gp-specific inhibitor PSC833 (5 M) (Hartz et al., 2004,
2008, 2010).
Western blotting. Protein expression levels in brain capillaries were
analyzed by Western blotting as previously described (Hartz et al., 2004,
2008, 2010). Briefly, brain capillaries were homogenized in CelLytic MT
cell lysis buffer (Sigma) containing Complete protease inhibitor (Roche).
Homogenized brain capillary samples were centrifuged at 10,000  g
for 15 min at 4°C to remove nuclei, followed by a centrifugation of the
denucleated supernatants at 100,000  g for 90 min at 4°C to obtain
brain capillary crude membranes. Brain capillary membranes were
resuspended in buffer containing protease inhibitor and stored at
80°C until use.
Western blotting was done using the Invitrogen NuPage Bis-Tris elec-
trophoresis and blotting system. After electrophoresis and protein trans-
fer (30 V, 2 h), PVDF membranes (0.45 m pore size) were blocked with
protein-free T20 blocking buffer (Pierce) and incubated overnight with
the primary antibody diluted in blocking buffer as indicated (C219,
-actin, ubiquitin, LRP, RAGE: all at 1 g/ml). PVDF blotting mem-
branes were washed and incubated with HRP-conjugated ImmunoPure
secondary IgG (1:15,000; Pierce) for 1 h. Proteins were detected using
SuperSignal West Pico Chemoluminescent Substrate (Pierce), and pro-
tein bands were visualized and imaged using a Bio-Rad Gel Doc 2000 gel
documentation system with Quantity One software (Bio-Rad).
Dot blotting. Dot blots were performed using the Whatman Minifold I
96-well system on Whatman Protran BA79 nitrocellulose membranes
(pore size 0.1 m, GE Healthcare). Blots were blocked, incubated,
washed, and imaged as described in Western blotting.
Immunoprecipitation. For immunoprecipitations, identical protein
amounts (determined by Bradford assay) of Protein A/G bead-
precleared capillary lysates were incubated with 5 g P-gp antibody over-
night at 4°C. The immune complexes were collected with Protein A/G
agarose beads (2 h, room temperature), washed four times with RIPA
buffer (150 mM NaCl, 1.0% IGEPAL CA-630, 0.5% sodium deoxy-
cholate, 0.1% SDS, 50 mM Tris, pH 8.0; Sigma-Aldrich) followed by a PBS
wash. For ubiquitin immunoprecipitations, a ubiquitin enrichment kit
from Pierce/Thermo Scientific was used according to the manufacturer’s
protocol. Immunoprecipitated proteins were eluted from agarose beads
(IP: P-gp) or the ubiquitin affinity resin (IP: ubiquitin) with NuPAGE
LDS sample buffer or Wes sample buffer and heated at 70°C for 10 min.
IP samples eluted with NuPAGE LDS sample buffer were resolved by
SDS-PAGE and analyzed by Western blotting as described above. Sam-
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ples eluted with Wes sample buffer (see Fig. 5D;
IP Ubiquitin) were analyzed and quantitated
with a Simple Western assay using the Wes
instrument (ProteinSimple). The Simple
Western assay is a capillary electrophoresis
technique that automates protein loading, sep-
aration, immunoprobing, washing, and detec-
tion, and allows absolute protein quantitation
(O’Neill et al., 2006; Beccano-Kelly et al.,
2014). For the assay, reagents of the Wes Mas-
ter Kit (ProteinSimple) were used, and all steps
of the assay were performed according to the
manufacturer’s protocol. A Wes Master Kit
capillary cartridge and the prepared microplate
were placed into the Wes instrument, which
processed all assay steps automatically using
default settings. Briefly, capillaries were loaded
with both stacking and separation matrices fol-
lowed by sample loading. During capillary
electrophoresis, proteins were separated by size
and then immobilized to the capillary wall.
P-gp and ubiquitin were identified with pri-
mary antibodies against P-gp (C219, Thermo
Scientific, 1:150) and ubiquitin (ubiquitin an-
tibody, Abcam, 1:20), respectively, followed by
immunodetection using Wes Master Kit HRP-
conjugated anti-mouse secondary antibody
and chemiluminescent substrate. Protein sig-
nals were automatically reported by the Com-
pass software (version 2.6.5; ProteinSimple).
Using Compass software, electropherograms
were generated for each capillary (treatment
group) and each protein (P-gp, ubiquitin), and
the area under the curve was analyzed for P-gp.
The area under the curve represents the signal
intensity of the chemiluminescent reaction and
is proportional to the amount of target protein
in a respective capillary.
20S proteasome activity assay. We used the
20S proteasome assay kit from Cayman Chem-
ical and followed the protocol provided by the
manufacturer. Isolated capillaries were lysed in
20S proteasomal lysis buffer. Capillary lysate
was incubated with 10 l assay buffer and 10 l
proteasome substrate (SUC-LLVY-AMC) for
1 h at 37°C. Fluorescence intensity (ex 360 nm,
em 480 nm) was measured using a microplate
reader.
Statistical analysis. Data are mean  SEM.
ANOVA or a two-tailed unpaired Student’s t
test was used to evaluate differences between
controls and treated groups using Microsoft
Excel 2010 and GraphPad Prism (version
6.01); differences were considered to be statis-
tically significant when p  0.05.
Results
Identification of A forms
For the experiments described in the pres-
ent study, we used 100 nM human A40
dissolved in PBS supplemented with 5 mM
D-glucose and 1 mM sodium pyruvate (pH
7.4, 25°C  0.5°C). We used several meth-
ods to identify the form in which A40
was present in this solution. These in-
volved measurements of A40 monomer
versus oligomer 0, 1, 6, and 24 h after
preparation of the A40 working solu-
Figure 1. Determination of A40 forms. A, Western blot showing bands for A40 at 4 kDa with 4G8 antibody (recognizes
A17–24), weak bands at 4 kDa with 6E10 antibody (recognizes A1–17), and no bands with A11 antibody (detects amyloid
oligomers) and faint bands with OC antibody (detects amyloid fibrils) 0, 1, 6, and 24 h after making the 100 nM A40 working
solution in PBS. B, Dot blots showing low A40 levels with 4G8, 6E10, A11, and OC antibodies that are decreasing over the course
of 24 h. C, Oligomer-specific configuration ELISA shows that the total amount of A40 in solution decreases over time.
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tion. With Western blotting (LDS-PAGE under reducing condi-
tions), we detected a band at 4 kDa for A40 monomer with 4G8
antibody (recognizes A17–24) and a weaker signal with 6E10
antibody (recognizes A1–17; Fig. 1A). However, by Western
blotting, we detected no A40 oligomer bands using A11 anti-
body (detects amyloid oligomers) and faint bands using OC an-
tibody (detects amyloid fibrils). Dot blot analysis using the same
antibodies indicated that A40 monomer and low levels of A40
oligomer were present in the solution, but the amount of A40
decreased over 24 h (Fig. 1B). By sandwich ELISA, we found a
decreasing amount of total A40 over time (Fig. 1C), which is
likely due to nonspecific binding of the A40 monomer to the test
tube. By an oligomer-specific configuration sandwich ELISA, we
observed a very low A40 oligomer signal. The total amount of all
A40 species detectable in solution decreased dramatically over
time. The lack of oligomeric A40 under these conditions is not
surprising as synthetic A40 oligomerizes weakly in vitro (LeVine,
2004). Thus, the 100 nM A40 solution used for our experiments
Figure 2. A40 reduces P-gp protein expression and transport function. Representative confocal microscopy images of isolated brain capillaries that were exposed to 100 nM A40 for 6 h and
then exposed to the fluorescent P-gp substrate NBD-CSA (marker for P-gp transport activity). A, Representative image of an isolated brain capillary after 1 h of exposure to 2 M NBD-CSA, showing
steady-state NBD-CSA fluorescence. B, NBD-CSA fluorescence in the capillary lumen is reduced in capillaries that were exposed to A40 for 6 h, indicating a decrease in P-gp transport activity. C,
Specific NBD-CSA fluorescence in the capillary lumen was obtained through analysis of the confocal images and shows decreased luminal fluorescence in capillaries exposed to 100 nM A40. D,
Western blot showing that 100 nM A40 reduces P-gp protein expression but has no effect on LRP or RAGE protein expression levels. E, Western blot showing that P-gp protein levels in capillaries
exposed to 10 –100 nM A40 for 1 h remain at control levels. In contrast, P-gp transport activity levels decreased. F, Western blot showing that P-gp protein and transport activity levels decreased
in a concentration-dependent manner after 6 h of A40 exposure. -Actin was used as protein loading control for Western blots. C, E, F, Data were obtained through analysis of the confocal images.
Specific NBD-CSA fluorescence is the difference between total luminal fluorescence and fluorescence in the presence of the specific P-gp inhibitor PSC833, representing specific P-gp transport
activity. Data are mean  SEM (n  10 –15 capillaries per treatment group from one brain capillary isolation; pooled tissue from 10 rats). Units are arbitrary fluorescence units (scale, 0 –255).
***p  0.001, significantly lower than control.
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primarily consisted of monomeric A40. In
an attempt to determine the size distribu-
tion of the various A40 forms in the solu-
tion/dispersion, we performed nanoparticle
tracking analysis using a NanoSight LM10
(Malvern Instruments). However, the A40
concentration (100 nM) was too low, and
the analysis was inconclusive (data not
shown). Overall, these results are consistent
with other findings showing that A40 re-
mains predominantly monomeric in aque-
ous buffer solutions, such as PBS (Stine et
al., 2011).
A40 reduces P-gp protein expression
and transport activity
We measured P-gp protein expression and
transport activity levels in freshly isolated rat
brain capillaries that were exposed to 100
nM human A40 for 1 or 6 h. After remov-
ing A40, P-gp transport activity was deter-
mined by incubating brain capillaries with
the P-gp-specific fluorescent substrate
NBD-CSA (2 M) and by measuring fluo-
rescence of this dye in the capillary lumens
by confocal microscopy and quantitative
image analysis as described previously
(Hartz et al., 2008, 2010). Figure 2 depicts
representative images of a control brain cap-
illary (no A40) and a brain capillary ex-
posed to A40 for 6 h. Luminal NBD-CSA
fluorescence was substantially decreased in
capillaries exposed to A40 compared with
control capillaries (Fig. 2A,B). Image anal-
ysis revealed a reduction of 69.46.2% (av-
erage of 10 independent experiments) in
luminal NBD-CSA in brain capillaries ex-
posed to A40, indicating that A40 re-
duced P-gp transport activity (Fig. 2C). This
result is consistent with our previous data in
isolated brain capillaries from wild-type and
transgenic hAPP mice, where we observed a comparable reduction
of P-gp transport activity levels with A40 exposure (Hartz et al.,
2010; their Fig. 2A,B). In addition to reduced P-gp transport activity,
we also found a reduction of 40.3  6.2% (average of 10 indepen-
dent experiments) in P-gp protein expression in brain capillary
membranes isolated from A40-treated brain capillaries (6 h treat-
ment). A40 exposure did not affect protein expression levels of
LRP1 (100  4% compared with control, average of three indepen-
dent experiments) and RAGE (95  5.6% compared with control,
average of three independent experiments; Fig. 2D). Dose–response
experiments showed that both 1 and 6 h exposure of brain capillaries
to 10, 50, and 100 nM A40 reduced P-gp transport activity in a
concentration-dependent manner, whereas only the 6 h exposure of
capillaries to A40 reduced P-gp protein expression levels (Fig.
2E,F). It is unlikely that A40 acts as P-gp inhibitor because A40-
mediated reduction the effect can be abolished by inhibitors of the
ubiquitin–proteasome pathway (data not shown). Thus, nanomolar
concentrations of human A40 trigger reduction of both P-gp ex-
pression and transport activity levels in isolated rat brain capillaries,
but the time courses of loss of transport activity and loss of trans-
porter protein expression levels differed.
To determine the effect of 100 nM A40 on P-gp transport activ-
ity over time, we preincubated isolated rat brain capillaries with 2 M
NBD-CSA for 1 h to a steady state before adding A40, and then
monitored brain capillaries over 6 h. Figure 3A shows that luminal
NBD-CSA fluorescence in control capillaries (no A40) did not
change over the 6 h time course (Hartz et al., 2010). In contrast,
addition of A40 reduced P-gp transport activity levels within 15
min. After 45 min, P-gp transporter activity was substantially de-
creased to a level that was comparable with that seen when P-gp was
inhibited with PSC833; P-gp transport activity remained at this low
level for the entire 6 h of A40 exposure. Removing A40 from the
buffer medium after 45 min restored P-gp transport activity to con-
trol levels over the course of 6 h.
P-gp protein expression levels were unchanged after a 45
min A40 exposure (Fig. 3B) and remained unchanged when
A40 was removed from the medium after 45 min and incu-
bation in A40-free medium continued for an additional 51⁄4 h
(Fig. 3C). In contrast, brain capillaries that were exposed to
A40 for a total of 6 h exhibited reduced P-gp protein expres-
sion levels (Fig. 3D). The A-mediated reduction of P-gp ex-
pression and transport activity levels was not reversible when
A40 was not removed after 45 min. Thus, A40-mediated
Figure 3. Time course of A40-mediated P-gp reduction. A, The effect of A40 on P-gp transport activity is reversible.
Capillaries were loaded for 60 min to steady state with 2 M NBD-CSA. When 100 nM A40 was added to the buffer (time 0 on
graph), P-gp transport activity decreased rapidly; P-gp activity stayed decreased in capillaries exposed to A40 for 6 h but
recovered completely when A40 was removed at time point 45 min. Western blot showing (B) no change of P-gp protein
expression after 45 min exposure to A40 and (C) no change of P-gp expression in capillaries that were first exposed to A40 for
45 min followed by 51⁄4 h in A40-free buffer (total experiment duration of 6 h). D, Consistent with Figure 2, Western blot showing
reduced P-gp protein expression after 6 h exposure to A40. -Actin was used as a protein loading control for all Western blots.
Data are mean  SEM (n  10 –15 capillaries per treatment group from one brain capillary isolation; pooled tissue from 10 rats).
Units are arbitrary fluorescence units (scale, 0 –255). *p  0.05, significantly lower than control. **p  0.01, significantly lower
than control. ***p  0.001, significantly lower than control.
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reduction of P-gp transport activity levels occurs within 15
min of initial A40 exposure followed by a reduction in P-gp
protein expression levels. The initial reduction in P-gp expres-
sion and transport activity levels is reversible when A40 ex-
posure of brain capillaries is limited to 45 min but becomes
irreversible when A40 remains in the medium for 45 min.
This indicates that the transporter is degraded after 45 min of
A40 exposure, after which P-gp expression and transport
activity cannot be restored.
In a series of control experiments, we exposed isolated rat
brain capillaries to the aggregated form of A40, to a peptide with
the reverse sequence of that for A40 (A40reverse), and to A42.
In contrast to monomeric A40, 6 h exposure of isolated rat brain
capillaries to aggregated A40 did not affect P-gp protein expres-
sion and transport activity (Fig. 4A,B). LRP and RAGE protein
expression levels also remained unchanged by the aggregated
form of A40. When we exposed isolated rat brain capillaries to
A40reverse (Fig. 4C) or to human A42 (Fig. 4D) for 6 h, P-gp
protein expression and transport activity did not change either.
These data indicate that, under these experimental conditions
(100 nM of respective human A species for 6 h), reduction in
P-gp protein expression and transport activity levels in isolated
rat brain capillaries is specific to A40, whereas aggregated A40,
A40reverse, or A42 had no effect.
Figure 4. Aggregated A40, reverse A40, and A42 have no effect on P-gp. Exposing capillaries to 100 nM A40 decreases P-gp protein expression (Western blot) and transport activity
(luminal NBD-CSA fluorescence). Aggregated A40 (A, B), A40reverse (reverse amino acid sequence of A40) (C), and A42 (D) had no effect on P-gp expression or activity. -Actin was used as
protein loading control for Western blots. Data are meanSEM (n10 capillaries per treatment group from one brain capillary isolation; pooled tissue from 10 rats). Units are arbitrary fluorescence
units (scale, 0 –255). ***p  0.001, significantly lower than control.
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A40 activates the ubiquitin–proteasome pathway
To determine whether exposure to human A40 triggers the re-
duction in P-gp protein expression and transport activity levels
by activating the ubiquitin–proteasome pathway, we exposed iso-
lated rat brain capillaries to 100 nM A40 for 6 h, immunopre-
cipitated P-gp or ubiquitin from capillary lysates, and separated
protein samples by SDS-PAGE and Western blotting. The West-
ern blot in Figure 5A (P-gp immunoprecipitation) shows in-
creased ubiquitin levels in brain capillaries treated with A40. In
the cross-experiment (Fig. 5B) where we immunoprecipitated
ubiquitin, we observed increased P-gp protein levels associated
with ubiquitin after A40 exposure. We detected no signal in the
IgG controls (capillary lysate sample plus IgG antibody) and neg-
ative controls (capillary lysate sample but no primary antibody;
Fig. 5A), indicating that the observed signals are specific for P-gp
and ubiquitin. Consistent with increased P-gp ubiquitination,
PYR-41, a cell-permeable inhibitor of ubiquitin ligase E1, abol-
ished the A40-mediated reduction of P-gp protein expression
and transport activity levels (Fig. 5C), as well as ubiquitination of
P-gp (Fig. 5D). Using the Simple Western assay system (Protein-
Simple), we determined the amount of P-gp that was immuno-
precipitated by ubiquitin: control samples contained 4.3 ng P-gp
protein, samples from capillaries exposed to A40 contained 6.9
ng P-gp protein, and samples treated with both A40 and PYR-41
contained 3.3 ng P-gp protein based on a P-gp protein standard
curve. Data from six independent immunoprecipitation experi-
ments indicate that A40 increased the amount of ubiquitinated
P-gp by 53  9.3%. Together, these data demonstrate that
Figure 5. A40 triggers ubiquitination of P-gp. A, Isolated capillaries were exposed to 100 nM A40. After 6 h, P-gp was immunoprecipitated and examined for P-gp and ubiquitin by Western
blotting. Capillaries exposed to A40 showed increased ubiquitination. IgG control: capillary lysate sample plus IgG antibody; negative control: capillary lysate sample but no primary antibody. B,
Cross-experiment showing immunoprecipitation of ubiquitin followed by Western blot analysis of P-gp and ubiquitin. Increased ubiquitination of P-gp was found in capillaries exposed to A40. C,
The ubiquitin ligase inhibitor PYR-41 (10 M) prevented A40-mediated reduction of P-gp expression (Western blot, -actin was used as protein loading control) and transport activity (luminal
NBD-CSA fluorescence). D, P-gp and ubiquitin were immunoprecipitated and examined for P-gp and ubiquitin by Western blotting and simple Western assay using the Wes instrument. PYR-41
prevented P-gp ubiquitination in capillaries exposed to 100 nM A40. Data are mean  SEM (n  10 capillaries per treatment group from one brain capillary isolation; pooled tissue from 10 rats).
Units are arbitrary fluorescence units (scale, 0 –255). ***p  0.001, significantly lower than control.
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A40 exposure increases P-gp ubiquitination in isolated brain
capillaries.
Next, we investigated whether A40 triggers internalization of
P-gp, which is the step following ubiquitination in the protea-
some pathway. We exposed isolated rat brain capillaries to A40
for 6 h with or without the microtubule inhibitors, brefeldin A
and nocodazole, to stop intracellular trafficking. Figure 6 shows
that both inhibitors blocked A40-mediated reduction of P-gp
protein expression and transport activity levels. These data sug-
gest that blocking intracellular trafficking prevents P-gp internal-
ization from the plasma membrane into the cell.
To verify that the final step of the ubiquitin–proteasome
pathway was involved in P-gp reduction, we determined whether
P-gp was subject to proteasomal or lysosomal degradation. We
exposed isolated rat brain capillaries to A40 with or without the
proteasome inhibitors lactacystin, MG-132, and bortzomib, or
the lysosomal vacuolar type H-ATPase inhibitor bafilomycin
A1. All three proteasome inhibitors prevented A40-mediated
reduction of P-gp protein expression and transport activity levels
(Fig. 7A–C), whereas the lysosomal inhibitor bafilomycin A1 had
no such effect (Fig. 7D). Consistent with this, we found increased
20S proteasomal activity in isolated rat brain capillaries that were
exposed to A40 for 6 h (Fig. 7E). The inhibitors themselves had
no effect on P-gp protein expression and transport function (Fig.
7F). This suggests that, following ubiquitination and internaliza-
tion, P-gp is directed to the proteasome for degradation.
Together, the present data demonstrate that exposing brain
capillaries to A40 triggers ubiquitination, internalization,
and proteasomal degradation of P-gp at the blood– brain bar-
rier (Fig. 8).
Discussion
We and others previously showed that P-gp protein expression
and transport activity are reduced in human A-overexpressing
AD mouse models (Hartz et al., 2010; Mehta et al., 2013). These
data are supported by studies with postmortem human brain
tissue that demonstrate P-gp expression and activity levels are
lower in the neurovasculature from patients with mild cognitive
impairment and AD compared with those in age-matched,
healthy individuals (Wijesuriya et al., 2010; Jeynes and Provias,
2011; van Assema et al., 2012; Deo et al., 2014). These studies
suggest a link between high A levels and reduced brain capillary
P-gp in AD. However, the cellular mechanism that drives P-gp
reduction in the blood– brain barrier in AD has not been
unraveled.
In the present study, we demonstrate that nanomolar concen-
trations of A40 decrease P-gp expression and transport activity
in rat brain capillaries and we begin to describe the mechanism
through which this occurs. Our data show that exposing brain
capillaries to monomeric A40 decreases P-gp protein expres-
sion and transport activity levels in a time- and concentration-
dependent manner (Figs. 1–3). At 100 nM, neither aggregated
A40, nor A40reverse, nor A42 had any effect (Fig. 4). A40
concentrations measured in postmortem brain tissue from AD
patients are in the mid to high nanomolar range, similar to the
A40 concentrations used in the present study (Gravina et al.,
1995; Hardy and Selkoe, 2002). Immunoprecipitation demon-
strated that A40 triggers P-gp ubiquitination, and experiments
with microtubule and proteasomal inhibitors indicate that P-gp
is internalized and degraded by the proteasome (Figs. 6, 7). Con-
Figure 6. Microtubule inhibitors prevent A40-mediated P-gp reduction. The microtubule inhibitors brefeldin A (1 g/ml) (A) and nocodazole (100 nM) (B) prevent A40-mediated reduction
of P-gp protein expression (Western blot) and transport activity (luminal NBD-CSA fluorescence). -Actin was used as protein loading control for Western blots. Data are mean  SEM (n  10
capillaries per treatment group from one brain capillary isolation; pooled tissue from 10 rats). Units are arbitrary fluorescence units (scale, 0 –255). ***p  0.001, significantly lower than control.
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sistent with this, 20S proteasomal activity in capillaries was in-
creased by A40. Based on these data, we propose that A40
activates the ubiquitin–proteasome system at the blood– brain
barrier, resulting in P-gp degradation and, thus, reduction in
P-gp protein expression and activity levels (Fig. 8). These data for
intact brain capillaries demonstrate a cause-and-effect relation-
ship between exposure to nanomolar concentrations of A40
and reduced P-gp expression and transport activity.
Recent reports suggest that A42 could also be involved in the
reduction of blood– brain barrier P-gp. Brenn et al. (2011) im-
planted an osmotic pump subcutaneously into FVB mice for 24 h
peripheral administration of A40 and A42, and showed that
A42, but not A40, slightly reduced P-gp mRNA levels in the
brain, whereas P-gp protein expression levels remained un-
changed. Carrano et al. (2014) exposed a human cerebral micro-
vascular endothelial cell line (hCMEC/D3) to various A forms
for 24 h and found that oligomeric A42, but not fibrillary A42
or A40, reduced P-gp mRNA levels. Park et al. (2014) showed
that A42-mediated reduction in P-gp protein expression in
bEnd.3 cells depended on RAGE and that a yet to-be-identified
astrocyte-derived factor attenuated the A-induced decrease in
P-gp expression in a bEnd.3-astrocyte coculture. However, the
Figure 7. Inhibition of the proteasome prevents A40-mediated P-gp reduction. The proteasome inhibitors lactacystin (10 M) (A), MG-132 (150 nM) (B), and bortezomib (100 nM) (C) abolish
A40-mediated reduction of P-gp expression (Western blot) and transport activity (luminal NBD-CSA fluorescence). D, The lysosomal inhibitor bafilomycin A1 (10 nM) did not prevent P-gp reduction
triggered by A40. E, The 20S proteasome activity was increased in isolated rat brain capillaries exposed to A40 for 6 h. -Actin was used as protein loading control for Western blots. F, The
inhibitors PYR-41, nocodazole, and bortzomib had no effect on P-gp protein expression and transport activity. Data are mean  SEM (n  10 capillaries per treatment group from one brain capillary
isolation; pooled tissue from 10 rats). Units are arbitrary fluorescence units (scale, 0 –255). ***p  0.001, significantly lower or higher than control.
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effects observed in these studies may not be a realistic reflection of
the situation in the AD brain because they may be artifacts
of administering A42 into the periphery (Brenn et al., 2011), of
using immortalized cultured cells (Carrano et al., 2014), and of
applying excessive A42 concentrations (Park et al., 2014). In
addition, it is possible that the A42 effect on blood– brain bar-
rier P-gp is time-, concentration-, and context-dependent, which
could explain some of the discrepancies between our data and
those by other groups described above.
Ubiquitination followed by lysosomal or proteasomal degra-
dation plays a crucial role in regulating expression and function
of membrane proteins (Ciechanover, 1994; Ciechanover and
Iwai, 2004). P-gp is a 180 kDa membrane protein that undergoes
endocytosis and recycling, and its half-life has been determined
in multidrug-resistant cancer cell lines to be 	14 –17 h (Muller et
al., 1995; Kim et al., 1997). P-gp trafficking, localization, stability,
and function are, in part, regulated by the ubiquitin–proteasome
pathway (Loo and Clarke, 1999). One protease-cleavage site of
P-gp is in the first extracellular loop near the glycosylation site
(Arg113); two more sites (Arg680 and Leu682) are located in the
linker region joining the two halves of P-gp (Loo and Clarke,
1998; Nuti and Rao, 2002). Zhang et al. (2004) were the first to
show that P-gp stability is regulated by the ubiquitin–proteasome
pathway. These authors found that inhibition of N-glycosylation
enhances P-gp ubiquitination and degradation, thereby reducing
transporter activity (Zhang et al., 2004). In a recent study, Katay-
ama et al. (2013) showed that the ubiquitin E3 ligase subunit
FBXO15 and the ubiquitin-conjugating enzyme E2 R1 regulate
P-gp expression in human colorectal cancer cell lines. The au-
thors demonstrated that FBXO15 knockdown increases cell-
surface P-gp expression and enhances P-gp-mediated efflux,
suggesting that the ubiquitin–proteasome system regulates P-gp
expression and activity levels. Our study indicates that A40 trig-
gers P-gp ubiquitination, internalization, and proteasome-
dependent degradation leading to reduction of P-gp expression
and activity levels in brain capillaries (Figs. 5–7). We show that
the lysosomal inhibitor bafilomycin A does not attenuate A40-
mediated P-gp reduction, suggesting that proteasomal degrada-
tion, rather than lysosomal degradation, reduces P-gp levels (Fig.
7). Recently, we demonstrated that P-gp is a substrate for the
ubiquitin ligase NEDD4-1, which is increased in brain capillaries
from 9-month-old hAPP mice (Tg2576 model) and may be in-
volved in A-mediated P-gp reduction
(Akkaya et al., 2015). A recent study by
Aida et al. (2014) on the ABC transporters
BSEP and MRP2 suggests that transporter
degradation is multifaceted and complex.
The authors propose that, in addition to
the ubiquitin–proteasome and lysosomal
pathways, proteins destined for degrada-
tion can also be routed to a ubiquitination-
independent, and bafilomycin-insensitive
pathway. Although our data are conclusive,
several mechanistic details remain to be de-
termined. For example, it is unknown
whether P-gp is mono- or poly-
ubiquitinated, which ubiquitin ligases cata-
lyze this step, and which signals drive A40
activation of the ubiquitin–proteasome
pathway.
The ubiquitin–proteasome system is
critical for normal brain function because
it regulates proper protein turnover, de-
velopment, and differentiation, signals transduction, and is re-
sponsible for the disposal of unneeded waste proteins (Yi and
Ehlers, 2007). In AD, however, the ubiquitin–proteasome system
is dysfunctional and is suspected to contribute to the pathogen-
esis of the disease (Oddo, 2008; Hong et al., 2014). In this regard,
the ubiquitin protein ligases, UBE2 and UBE3, are upregulated in
AD, and elevated levels of ubiquitinated proteins have been de-
tected in neurofibrillary tangles and A plaques in postmortem
AD brains (Mori et al., 1987; Perry et al., 1987; Keck et al., 2003).
Overall, the majority of available studies suggest that the ubiquit-
in–proteasome system is impaired and defective in neurons in the
late-stage AD brain from deceased patients. In contrast, little is
known about changes in the subset of the ubiquitin–proteasome
system at the blood– brain barrier. In this regard, Deane et al.
(2004) showed A-mediated proteasomal degradation of LRP in
brain capillaries from 6- to 9-month-old, transgenic hAPP mice
that were cognitively impaired. In isolated brain capillaries
from nontransgenic wild-type mice, we found that A40 in-
creases proteasome activity and ubiquitinylated P-gp levels,
resulting in reduced P-gp expression and activity levels (Figs.
5–7). Thus, our data support a possible role for the ubiquitin–
proteasome system in reducing P-gp in AD at the level of the
blood– brain barrier.
The present experiments show that the time courses of A40-
induced loss of P-gp transport activity and protein expression do
not coincide. Transport activity decreased rapidly with A40 ex-
posure, whereas the reduction in transporter expression was de-
layed (at least past 45 min of exposure). Removal of A40 early in
the time course fully restored transport activity and did not alter
transporter expression in the long term. In 6 h experiments, phar-
macologically inhibiting P-gp ubiquitination, trafficking, or deg-
radation at the proteasome abolished the loss of transporter
activity and transporter protein expression. One would expect
this result when ubiquitination was inhibited, but the lack of
effect of A40 exposure when trafficking and proteasomal deg-
radation were inhibited suggests a more complex scenario than
that depicted in Figure 8. One possibility for P-gp is that both
ubiquitination and trafficking are reversible when degradation
does not occur over a period of hours. These aspects of the mech-
anism require further study, as does the mechanism by which
A40 signals P-gp ubiquitination, internalization, and protea-
some activation.
Figure 8. Proposed signaling pathway. Based on the data presented here, we propose the following signaling pathway: A40
triggers: (1) ubiquitination, (2) internalization, and (3) proteasomal degradation of blood– brain barrier P-gp, which results in
reduced P-gp protein expression and transport function.
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Collectively, our findings and those from other groups indi-
cate that P-gp in the blood– brain barrier is part of the A brain
clearance system and that P-gp protein expression and transport
activity levels are reduced in AD (Lam et al., 2001; Cirrito et al.,
2005; Kuhnke et al., 2007; Hartz et al., 2010; Mehta et al., 2013).
We also demonstrate in rat brain capillaries that A40 triggers
reduction in P-gp expression and activity levels through the ubiq-
uitin–proteasome system, which, for the first time, provides a
plausible mechanism how P-gp is reduced in AD. This implies a
pernicious positive feedback loop where reduced P-gp levels lead
to increased A brain accumulation, which in turn drives further
P-gp degradation, leading to even greater increases in A brain
levels and eventually AD pathology. Clearly, this scenario could
contribute to the progressive nature of AD. In this regard, our
data imply that the ubiquitin–proteasome system may poten-
tially serve as an early therapeutic target to protect P-gp from
degradation and limit A from accumulation in the brain,
thereby delaying the onset and slowing the progression of AD.
Current studies are underway to test the effect of PYR-41, no-
codazole, and bortezomib in an AD mouse model in vivo.
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